What we found on the web about Biosimilar
Biosimilar - Wikipedia, the free encyclopedia
Biosimilars or Follow-on biologics are terms used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry.
Intas Biopharmaceuticals - Wikipedia, the free encyclopedia
Intas Biopharmaceuticals Ltd. is an Indian biotechnology company headquartered in Ahmedabad, India. Located in the Moraiya,Ahmedabad,it is one of the leading biosimilar product ...
Guideline on Similar Biological Medicinal Products
These guidelines are available at the following location on the EMEA website: http: //www. eme a. eu. in t/index/indexh1. htm (Guidance Documents / Biosimilar Products) The current ...
The Weeks of June 18, June 25, July 2, July 9, and July 16 in Review
A biosimilar product will be approved if there is a demonstration that there are ... FDA may determine that a biosimilar product is interchangeable if it "can be ...
BioMarket Group - Negotiating the Emerging Biosimilars Landscape
This report examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market.
Article: Negative Opinion On Biosimilar Drug
Register today for a free trial, credit card req'd. Find Pharmaceutical Technology Europe articles plus many other academic journal articles, magazine articles & news...
Biosimilar — Blogs, Pictures, and more on WordPress
Global biosimilar Market: Changing. The biotechnology has changed the outlook of pharmaceutical market. Pharmaceutical in combination with biotechnology has evolved a new branch ...
Biosimilar Insulins: Are they really ‘similar’ ?
Insulin Analogues in Modern Diabetes Management: Biosimilar Insulins: Are they really ‘similar’ ? Shashank R Joshi. Consultant Endocrinologist, Joshi Clinic, Lilavati & Bhatia ...
Pharmalicensing.com: Reports database: Report searching
Price may be the key factor affecting biosimilar epoetin uptake ... factor has attracted many biosimilar companies. Biosimilar Enbrel presents a very lucrative ...
European regulation and policy governing biosimilar products
product (biosimilar) was introduced in the new. pharmaceutical law ... approval of biosimilar products found in ... force for biosimilar products under ...
INTAS Plans Filgrastim launch in North America, Europe
Intas Biopharma is a part of Cooperation between three continents for Biosimilar GCSF - India PRwire ... guidelines for biosimilar product registration in ...
Novartis on the Biosimilar Attack
The Motley Fool - The EU market welcomes the drugmaker's copy of a treatment for anemia. ... Novartis' biosimilar that received the go-ahead is a compound that ...
The Top 10 Biosimilar Players: Positioning, performance and SWOT ...
Source: Business InsightsPrice: $3835Date Published: April 20, 2009Biologics continue to outperform the global pharma market, driven by premium priced therapies for ...
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Biosimilar

Biosimilars or Follow-on biologics are terms used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Biosimilar
Pfizer chairman backs biologic drug generics
St. Louis Post-Dispatch
With Pfizer Inc. about to acquire rival drug maker Wyeth and its expertise in making pricey and complex biologic drugs, Pfizer Chief Executive Jeffrey Kindler strongly supports allowing generic versions of them.
HR 3962 page numbers -- Divisions C and D
DAILY KOS
Licensure pathway for biosimilar biological products. page 1560 Sec. 2576. Fees relating to biosimilar biological products. page 1561 Sec. 2577. Amendments to certain patent provisions. page 1562 ‘‘Sec. 3201. Purpose. page 1563 ‘‘Sec. 3202.
Access to US biosimilars market set to get tougher
Daily News and Analysis
The US is considering a measure that would prevent the US Food and Drug Administration (FDA) from approving a biosimilar (off-patent version of a biopharmaceutical drug) until 12 years have passed since the innovator biologic was first appr...
Assessing Biosimilars In Practice: Considerations For The Hospital Pharmacist To Evaluate
Medical News Today
Hospira (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today sponsored a satellite symposium at the European Association of Hospital Pharmacists (EAHP) congress. The symposium focussed on the information a pharmacist m...
Pfizer CEO: Best to back parts of health reform
San Francisco Chronicle
With Pfizer Inc. about to acquire rival drugmaker Wyeth and its expertise in making pricey and complex biologic drugs, Pfizer CEO Jeffrey Kindler strongly supports allowing generic versions of them. "Done right, with regard to the safety of...
Research and Markets: Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment
Business Wire via Yahoo! Finance
DUBLIN, Ireland----Research and Markets has announced the addition of the "Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment" report to their offering.
Rep. Eshoo on Health Care Reform Bill
All American Patriots
R. 3962, to create an FDA pathway for the approval of biosimilar drugs. "Biotechnology is a complex and emerging field that can harness the power to cure cancer , AIDS, and diabetes , and prevent the onset of deadly and debilitating disease...